Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 6
2006 6
2007 6
2008 3
2009 3
2010 4
2011 3
2012 6
2013 8
2014 5
2015 4
2016 7
2017 6
2018 11
2019 12
2020 16
2021 13
2022 7
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Results by year

Filters applied: . Clear all
Page 1
Substitution at boron in BODIPYs.
Gapare RL, Thompson A. Gapare RL, et al. Among authors: thompson a. Chem Commun (Camb). 2022 Jun 30;58(53):7351-7359. doi: 10.1039/d2cc02362h. Chem Commun (Camb). 2022. PMID: 35722959 Review.
Current practices in managing end-of-life existential suffering.
Di Risio M, Thompson A. Di Risio M, et al. Among authors: thompson a. Curr Opin Support Palliat Care. 2023 Jun 1;17(2):119-124. doi: 10.1097/SPC.0000000000000646. Epub 2023 Apr 10. Curr Opin Support Palliat Care. 2023. PMID: 37039587 Review.
Robust synthesis of F-BODIPYs.
Beh MH, Douglas KI, House KT, Murphy AC, Sinclair JS, Thompson A. Beh MH, et al. Among authors: thompson a. Org Biomol Chem. 2016 Dec 28;14(48):11473-11479. doi: 10.1039/c6ob02238c. Epub 2016 Nov 24. Org Biomol Chem. 2016. PMID: 27883144
BODIPYs with Chalcogenophenes at Boron: Synthesis and Properties.
Campbell JW, Tung MT, Robertson KN, Beharry AA, Thompson A. Campbell JW, et al. Among authors: thompson a. J Org Chem. 2023 Aug 4;88(15):10655-10661. doi: 10.1021/acs.joc.3c00708. Epub 2023 Jul 13. J Org Chem. 2023. PMID: 37439486
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
122 results